AlphaCentric Advisors’s Neurocrine Biosciences NBIX Stock Holding History

AlphaCentric Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.27M	Buy	9,607 +2,224	+30%	+$295K	1.26%	13
2025 Q4	$1.05M	Buy	+7,383	New	+$1.07M	1.04%	17
2024 Q4	$503K	Sell	3,684 -18,816	-84%	-$2.33M	0.5%	56
2024 Q3	$2.59M	Buy	22,500 +15,500	+221%	+$2.12M	1.93%	6
2024 Q2	$964K	Hold	7,000	–	–	0.71%	49
2024 Q1	$965K	Buy	+7,000	New	+$956K	0.58%	64
2023 Q4	–	Sell	-30,000	Closed	-$3.38M	–	269
2023 Q3	$3.38M	Sell	30,000 -6,500	-18%	-$684K	1.91%	9
2023 Q2	$3.44M	Buy	36,500 +21,000	+135%	+$2.05M	1.91%	7
2023 Q1	$1.57M	Buy	+15,500	New	+$1.61M	1.08%	22
2021 Q2	–	Sell	-2,000	Closed	-$195K	–	233
2021 Q1	$195K	Sell	2,000 -800	-29%	-$83.9K	0.07%	94
2020 Q4	$268K	Buy	2,800 +2,500	+833%	+$241K	0.11%	47
2020 Q3	$29K	Buy	300 +75	+33%	+$8.68K	0.01%	131
2020 Q2	$27K	Buy	+225	New	+$24.9K	0.02%	107

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaCentric Advisors's NBIX Position: Q1 2026 in Review

AlphaCentric Advisors increased its Neurocrine Biosciences (NBIX) stake by 30% in Q1 2026, buying an estimated $295K and bringing the position to 9,607 shares worth $1.27M. The position accounts for 1.26% of the portfolio, ranked #13.

AlphaCentric Advisors first reported a position in NBIX in Q2 2020 and has held it in 13 quarters since. The position peaked at $3.44M in Q2 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

AlphaCentric Advisors held 9,607 shares of Neurocrine Biosciences worth $1.27M as of Q1 2026.
AlphaCentric Advisors bought 2,224 Neurocrine Biosciences shares in Q1 2026, an estimated $295K.
Neurocrine Biosciences made up 1.26% of AlphaCentric Advisors's portfolio in Q1 2026, its #13 holding.
AlphaCentric Advisors first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 13 quarters since.
AlphaCentric Advisors's Neurocrine Biosciences position peaked at $3.44M in Q2 2023.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.